Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 4/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681378 | 0.89 | L3MBTL1 (0.43) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL760556 | 0.86 | KMT2A (0.51) | L3MBTL1MEN1KMT2A | |
| SCHEMBL13262985 | 0.85 | L3MBTL1 (0.41) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL16503789 | 0.83 | L3MBTL1 (0.40) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL18487086 | 0.82 | L3MBTL1 (0.45) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL424580 | 0.82 | L3MBTL1 (0.48) | L3MBTL1AKT1FABP4NOTUMBRD4 | |
| SCHEMBL3836430 | 0.82 | L3MBTL1 (0.45) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL3175931 | 0.81 | ALDH1A1 (0.46) | L3MBTL1BRD4CREBBPMEN1KMT2A | |
| SCHEMBL2878376 | 0.81 | NOTUM (0.63) | L3MBTL1AKT1NOTUMBRD4CREBBP | |
| SCHEMBL18788881 | 0.81 | L3MBTL1 (0.44) | L3MBTL1AKT1NOTUMBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20240360103-A1 | COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2024-10-31 | — | — | US | disclosed |
| EP-3523292-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-15 | — | — | EP | disclosed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | disclosed |
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2021-02-09 | — | — | US | disclosed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | disclosed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102442941-A | Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2012-05-09 | — | — | CN | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| CN-101636386-A | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC | 2010-01-27 | — | — | CN | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008072784-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2008-06-19 | — | — | WO | disclosed |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2005026114-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913730-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB4 | L3MBTL1 881/4885AKT1 64/4885FABP4 4484/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | L3MBTL1 1353/4885AKT1 59/4885FABP4 4516/4885 |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | L3MBTL1 4881/4885AKT1 3802/4885FABP4 3549/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | L3MBTL1 881/4885AKT1 64/4885FABP4 4484/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | L3MBTL1 1353/4885AKT1 59/4885FABP4 4516/4885 |
| US-20240360103-A1 | COMPLEMENT INHIBITION | C5, C9, C1QBP | L3MBTL1 485/4885AKT1 3182/4885FABP4 4368/4885 |
| US-20050124683-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | PEPD, SERPINB1, ACE | L3MBTL1 3722/4885AKT1 1879/4885FABP4 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.